Citations

Showing 10 of 108162 citations.

Letter to the Editor Regarding a Recent Article: Meta-Analysis Comparing Celecoxib with Diclofenac Sodium in Patients with Knee Osteoarthritis
Moman, Rajat N. , Hooten, W. Michael , Moman, Rajat

Mayo Clinic

Pain Medicine | March 13, 2021 | Volume: 23 | Issue: 3 | Pages: 595-696

10.1093/pm/pnab100 | PMID 33724403 Get It

Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study
Pinter, Andreas , Bouaziz, Jean‐David , Wollenberg, Andreas , Alpizar, Sady , Laquer, Vivian , Chaouche, Kamel, Armstrong, J. , Piketty, Christophe , Silverberg, J I , Pinter, A , Bouaziz, J-D , Wollenberg, A , Piketty, C , Alavi, Afsáneh , Lynde, Charles W , Murrell, D F , Ahmad, F., Armstrong, J.M.

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | March 12, 2021 | Volume: 35 | Issue: 7 | Pages: 1562-1568

10.1111/jdv.17218 | PMID 33711179 Get It

AbstractBackgroundNemolizumab is a humanized anti‐IL‐31 receptor blocker in phase 3 for atopic dermatitis (AD).ObjectiveAnalyse onset of action of nemolizumab 30 mg and compare efficacy and safety vs placebo (SC q4wk plus loading dose) in moderate‐to‐severe AD.MethodsPost hoc analysis of patients with Eczema Area and Severity Index (EASI) scores ≥ 16 from a phase 2b trial of moderate‐to‐severe AD. Endpoints were change in EASI score at week 16, peak pruritus numeric rating scale (PP‐NRS), Investigator’s Global Assessment (IGA), changes in sleep and responders with ≥ 4‐point improvement on PP‐NRS.ResultsThere was a significantly greater itch relief apparent by Day 2 (−22.8% vs –12.3% PP‐NRS; P = 0.005) which continued to improve through week 16 (−68.5% vs −30.9% PP‐NRS; P < 0.001). At week 16, PP‐NRS ≥ 4‐point response of itch was observed in 68.0% nemolizumab vs 15.9% placebo patients (P ≤ 0.001). There was also a rapid improvement of sleep disturbance with nemolizumab 30 mg, with a significant separation from placebo by Day 3 (−26.6% vs –9.0%; P < 0.001) which further improved till week 16 (−76.0% vs −36.5%; P < 0.001). Also for the EASI score a separation between groups in favour of nemolizumab was observed by week 1 (P ≤ 0.001), which increased through week 16 (−68.6% vs. −42.6%; P = 0.002). Finally, the degree of response was greater in nemolizumab‐treated patients; clinically relevant reductions of 75% EASI were observed in 50.0% of nemolizumab patients versus 15.9% of placebo patients, while 90% reductions were reported for 36.0% and 6.8% of patients, respectively (P < 0.001 for both). IGA success (score of 0/1) was 32.0% for nemolizumab vs 6.8% for placebo (P = 0.002).Nemolizumab was safe and well‐tolerated in this population; nasopharyngitis and upper respiratory tract infection were the most common adverse events.ConclusionsNemolizumab resulted in very rapid, sustained improvements of inflammation, pruritus and sleep in patients with EASI ≥ 16 at baseline.
Systematic Analysis of Extracting Data on Advance Directives from Patient Electronic Health Records (EHR) in Terminal Oncology Patients
Starr, Jason S. , Skelton, William Paul , Rahmanian, Kiarash P., Guenther, Robert, Allen, William L. , George, Thomas J. , Moseley, Ray , George, Thomas J

Mayo Clinic

Journal of Palliative Care | March 12, 2021 | Volume: 36 | Issue: 4 | Pages: 211-218

10.1177/08258597211001153 | PMID 33711237 Get It

Background: Advance directives are legal documents that include living wills and durable health care power of attorney documents. They are critical components of care for seriously ill patients which are designed to be implemented when a patient is terminally ill and incapacitated. We sought to evaluate potential reasons for why advance directives were not appropriately implemented, by reviewing the electronic health record (EHR) in patients with terminal cancer. Methods: A retrospective analysis of the EHR of 500 cancer patients from 1/1/2013 to 12/31/2016 was performed. Data points were manually collected and entered in a central database. Results: Of the 500 patients, 160 (32%) had an advance directive (AD). The most common clinical terminology used by physicians indicating a terminal diagnosis was progressive (36.6%) and palliative (31%). The most common clinical terminology indicating incapacity was altered mental status (25.6%), and not oriented (14%). 34 (6.8%) patients met all criteria of having a terminal diagnosis, a documented AD, and were deemed incapacitated. Of these patients who met all of these data points, their ADs were implemented on average 1.7 days (SD: 4.4 days) after which they should have been. This resulted in a total of 58 days of additional care provided. Discussion: This study provided insight on to how ADs are managed in day to day practice in the hospital. From our analysis it appears that physicians are able to identify when a patient is terminal, however, it is typically later than it should have been recognized. Further studies should be performed focusing on harnessing the power of the EHR and providing physicians formative and evaluative feedback of practice patterns to ensure that ADs are honored when appropriate.
Reply
Izzy, Manhal , Lin, Grace , Watt, Kymberly D.

Mayo Clinic

Liver Transplantation | March 12, 2021 | Volume: 27 | Issue: 7 | Pages: 1070-1070

10.1002/lt.26048 | PMID 33711189 Get It

Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Bergan, Stein , Hesselink, Dennis A. , Johnson‐Davis, Kamisha L. , Kunicki, Paweł K. , Lemaı̂tre, F. , Marquet, Pierre , Molinaro, Mariadelfina , Noceti, Ofelia , Pattanaik, Smita , Seger, Christoph , Shipkova, Maria , Swen, Jesse J. , Gelder, Teun van , Venkataramanan, Raman , Wieland, Eberhard , Woillard, Jean‐Baptiste , Zwart, Tom C. , Barten, M.J., Budde, Klemens , Haufroid, Vincent , Millán, Olga , Mizuno, Tomoyuki , Oellerich, Michael , Salzmann, Linda, Tönshoff, Burkhard , Schaik, Ron H. N. van , Vethe, Nils Tore , Vinks, Alexander A. , Wallemacq, Pierre, Åsberg, Anders , Langman, Loralie J., Budde, Klemens , Brunet, Merçè , Pawiński, Tomasz , Dieterlen, Maja‐Theresa , Elens, Laure , Masuda, Satohiro , Moes, Dirk Jan A. R. , Picard, Nicolas

Mayo Clinic

Therapeutic Drug Monitoring | March 12, 2021 | Volume: 43 | Issue: 2 | Pages: 150-200

10.1097/ftd.0000000000000871 | PMID 33711005 Get It

Abstract: When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy, fixed doses were recommended by the manufacturer. Awareness of the potential for a more personalized dosing has led to development of methods to estimate MPA area under the curve based on the measurement of drug concentrations in only a few samples. This approach is feasible in the clinical routine and has proven successful in terms of correlation with outcome. However, the search for superior correlates has continued, and numerous studies in search of biomarkers that could better predict the perfect dosage for the individual patient have been published. As it was considered timely for an updated and comprehensive presentation of consensus on the status for personalized treatment with MPA, this report was prepared following an initiative from members of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT). Topics included are the criteria for analytics, methods to estimate exposure including pharmacometrics, the potential influence of pharmacogenetics, development of biomarkers, and the practical aspects of implementation of target concentration intervention. For selected topics with sufficient evidence, such as the application of limited sampling strategies for MPA area under the curve, graded recommendations on target ranges are presented. To provide a comprehensive review, this report also includes updates on the status of potential biomarkers including those which may be promising but with a low level of evidence. In view of the fact that there are very few new immunosuppressive drugs under development for the transplant field, it is likely that MPA will continue to be prescribed on a large scale in the upcoming years. Discontinuation of therapy due to adverse effects is relatively common, increasing the risk for late rejections, which may contribute to graft loss. Therefore, the continued search for innovative methods to better personalize MPA dosage is warranted.
The outcomes of secondary AML post allogeneic hematopoietic cell transplantation significantly depend on the presence of poor‐risk cytogenetic abnormalities
Hassanein, Mona , Rasheed, Walid , Ahmed, Syed Osman, Shaheen, Marwan , Chaudhri, Naeem , Alsharif, Fahad , Ahmed, Shad, Hanbali, Amr , Alshaibani, Alfadel , Alfraih, Feras , Alhayli, Saud, Alzahrani, Hazzaa , Almohareb, Fahad , Aljurf, Mahmoud , Hashmi, Shahrukh K. , Hanbali, Amr , Hashmi, Shahrukh, Fakih, Riad El , Elhassan, Tusneem Ahmed M. , Alahmari, Ali Debsan

Mayo Clinic

eJHaem | March 12, 2021 | Volume: 2 | Issue: 2 | Pages: 249-256

10.1002/jha2.136 | PMID 35845278 Get It

AbstractSecondary acute myeloid leukemia (sAML) includes AML as a complication of an antecedent hematological disorder or a therapy‐related AML. Large registry‐based data identified sAML as an independent poor‐outcome type of AML post allogeneic hematopoietic cell transplantation (allo‐HCT). In our study, we tried to define factors affecting outcomes of sAML post allo‐HCT, and identify patients with sAML who may truly benefit from allo‐HCT. We retrospectively analyzed the data of 64 patients aged (14‐61 years) with sAML who received allo‐HCT between September 2010 and February 2018 at our institute. Most of the patients were transplanted from matched related donors (MRD; 54, 84.4%). Our results showed that poor‐risk cytogenetics were identified in 31 patients (48.4%), and their presence was an indicator of poor overall survival (OS) and disease‐free survival (DFS; P‐value = .009, and .004, respectively). The cumulative incidence of chronic graft‐versus‐host disease (cGVHD) was significantly lower in sAML patients with poor‐risk cytogenetics (P‐value = .003) resulting in a high risk of death without cGVHD in this group of patients (P‐value = .02). Besides, GVHD relapse‐free survival (GRFS) analysis showed that most of our studied patients experienced either relapse or debilitating grade II‐IV cGVHD in the first 2 years post allo‐HCT. We conclude that sAML patients with poor‐risk cytogenetics have a significantly lower DFS post allo‐HCT with a high risk of death without active cGVHD.
Fascia Iliaca Block for Postoperative Pain Control After Hip Arthroscopy: A Systematic Review of Randomized Controlled Trials
Smith, John-Rudolph H. , Kraeutler, Matthew J. , Keeling, Laura E. , Scillia, Anthony J. , McCarty, Eric C. , Mei-Dan, Omer , Smith, John R. , McCarty, Eric C , Smith, John-Rudolph

Mayo Clinic

The American Journal of Sports Medicine | March 12, 2021 | Volume: 49 | Issue: 14 | Pages: 4042-4049

10.1177/0363546521996713 | PMID 33710936 Get It

Background: Various analgesic modalities have been used to improve postoperative pain in patients undergoing hip arthroscopy. Purpose: To systematically review the literature to compare the efficacy of the fascia iliaca block (FIB) with that of other analgesic modalities after hip arthroscopy in terms of postoperative pain scores and analgesic consumption. Study Design: Systematic review. Methods: A systematic review was performed by searching PubMed, the Cochrane Library, and Embase up to April 2020 to identify randomized controlled trials that compared postoperative pain and analgesic consumption in patients after hip arthroscopy with FIB versus other pain control modalities. The search phrase used was “hip arthroscopy fascia iliaca randomized.” Patients were evaluated based on postoperative pain scores and total postoperative analgesic consumption. Results: Five studies (3 level 1, 2 level 2) were identified that met inclusion criteria, including 157 patients undergoing hip arthroscopy with FIB (mean age, 38.3 years; 44.6% men) and 159 patients among the following comparison groups: lumbar plexus block (LPB), intra-articular ropivacaine (IAR), local anesthetic infiltration (LAI), saline placebo, and a no-block control group (overall mean age, 36.2 years; 36.5% men). No significant differences in pain scores were reported in the postanesthesia care unit (PACU) between the FIB and LPB (3.4 vs 2.9; P = .054), IAR (7.7 vs 7.9; P = .72), control group (no FIB: 4.1 vs 3.8; P = .76); or saline placebo (difference, –0.2 [95% CI, –1.1 to 0.7]). One study reported significantly higher pain scores at 1 hour postoperation in the FIB group compared with the LAI group (5.5 vs 3.4; P = .02). Another study reported significantly greater total analgesic consumption (in morphine equivalent dosing) in the PACU among the FIB group compared with the LPB group (20.8 vs 17.0; P = .02). No significant differences were observed in total PACU analgesic consumption between FIB and other analgesic modalities. Conclusion: In patients undergoing hip arthroscopy, the FIB does not appear to demonstrate superiority to other forms of analgesics in the immediate postoperative period. Therefore, it is not recommended as a routine form of pain control for these procedures.
Performance of Swedish children on a dynamic motor speech assessment
Rex, Susanne , Hansson, Kristina , McAllister, Anita , Strand, Edythe, McAllister, Anita , Hansson, Kristina

Mayo Clinic

International Journal of Speech-Language Pathology | March 12, 2021 | Volume: 23 | Issue: 5 | Pages: 453-464

10.1080/17549507.2020.1862300 | PMID 33709846 Get It

Contralateral Rerouting of Hypoglossal Nerve Implant Pulse Generator and Stimulation Lead
Macielak, Robert J. , Olson, Eric J. , Junna, Mithri R. , Olson, Michael D.

Mayo Clinic

The Laryngoscope | March 12, 2021 | Volume: 131 | Issue: 7 | Pages: No page available

10.1002/lary.29463 | PMID 33710618 Get It

AbstractAs use of hypoglossal nerve stimulators has become more widespread in the treatment of obstructive sleep apnea, certain scenarios have dictated alterations to the previously described surgical technique. This report describes a situation in which revision of a hypoglossal nerve stimulator implant was required given the need for breast cancer surgery. It serves as the first description of the contralateral rerouting of a stimulation lead to a left‐sided impulse generator and the first description of respiratory sensing lead placement within the left second intercostal space for such a device. Laryngoscope, 131:E2409–E2412, 2021
Segregation of functional networks is associated with cognitive resilience in Alzheimer’s disease
Ewers, Michael , Luan, Ying , Frontzkowski, Lukas , Rubinski, Anna , Dichgans, Martin , Hassenstab, Jason , Gordon, Brian A. , Chhatwal, Jasmeer P. , Xiong, Chengjie , Morris, John C. , Goate, Alison , Fagan, Anne M. , Berman, Sarah , Chui, Helena C., Cruchaga, Carlos , Farlow, Marty, Graff‐Radford, Neill R. , Martins, Ralph N. , Mori, Hiroshi , Perrin, Richard J. , Xiong, Chengjie , Fox, Nick C. , O’Connor, Antoinette , Salloway, Stephen , Danek, Adrian , Büerger, Katharina , Bateman, Randall J. , Habeck, Christian , Network, for the Alzheimer’s Disease Neuroimaging Initiative and the Dominantly Inherited Alzheimer, Vöglein, Jonathan , Gordon, Brian A , O'Connor, Antoinette , Stern, Yaakov , Franzmeier, Nicolai , Dichgans, Martin , Cruchaga, Carlos , Bateman, Randall J , Vöglein, Jonathan , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Berman, Sarah , Neitzel, Julia , Schofield, Peter R. , Benzinger, Tammie L.S. , Karch, Celeste M. , McDade, Eric , Allegri, Ricardo , Chui, Helena C. , Jucker, Mathias , Lee, Jae‐Hong , Rossor, Martin N. , Stern, Yaakov , Franzmeier, Nicolai , Network, for the Alzheimer’s Disease Neuroimaging Initiative and the Dominantly Inherited Alzheimer

Mayo Clinic

Brain | March 12, 2021 | Volume: 144 | Issue: 7 | Pages: 2176-2185

10.1093/brain/awab112 | PMID 33725114 Get It

Abstract Cognitive resilience is an important modulating factor of cognitive decline in Alzheimer’s disease, but the functional brain mechanisms that support cognitive resilience remain elusive. Given previous findings in normal ageing, we tested the hypothesis that higher segregation of the brain’s connectome into distinct functional networks represents a functional mechanism underlying cognitive resilience in Alzheimer’s disease. Using resting-state functional MRI, we assessed both resting-state functional MRI global system segregation, i.e. the balance of between-network to within-network connectivity, and the alternate index of modularity Q as predictors of cognitive resilience. We performed all analyses in two independent samples for validation: (i) 108 individuals with autosomal dominantly inherited Alzheimer’s disease and 71 non-carrier controls; and (ii) 156 amyloid-PET-positive subjects across the spectrum of sporadic Alzheimer’s disease and 184 amyloid-negative controls. In the autosomal dominant Alzheimer’s disease sample, disease severity was assessed by estimated years from symptom onset. In the sporadic Alzheimer’s sample, disease stage was assessed by temporal lobe tau-PET (i.e. composite across Braak stage I and III regions). In both samples, we tested whether the effect of disease severity on cognition was attenuated at higher levels of functional network segregation. For autosomal dominant Alzheimer’s disease, we found higher functional MRI-assessed system segregation to be associated with an attenuated effect of estimated years from symptom onset on global cognition (P = 0.007). Similarly, for patients with sporadic Alzheimer’s disease, higher functional MRI-assessed system segregation was associated with less decrement in global cognition (P = 0.001) and episodic memory (P = 0.004) per unit increase of temporal lobe tau-PET. Confirmatory analyses using the alternate index of modularity Q revealed consistent results. In conclusion, higher segregation of functional connections into distinct large-scale networks supports cognitive resilience in Alzheimer’s disease.